At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGON CG Oncology Inc.
Pre-Mkt 04-07 06:05:37 EDT
67.55
+0.07
+0.10%
盘前67.05
-0.50-0.74%
05:21 EDT
High68.90Low66.90Vol1.14M
Open67.54D1 Closing67.48Amplitude2.96%
Mkt Cap5.70BTradable Cap4.58BTotal Shares84.44M
T/O77.09MT/O Rate1.68%Tradable Shares67.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CG Oncology, Inc. : H.c. Wainwright Raises Target Price to $100 From $80
THOMSON REUTERS  ·  14 minutes ago
CG Oncology, Inc. : H.c. Wainwright Raises Target Price to $100 From $80
CG Oncology, Inc. (CGON) Gets a Buy from JonesTrading
TIPRANKS  ·  04:37
CG Oncology, Inc. (CGON) Gets a Buy from JonesTrading
A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering
Simply Wall St.  ·  04-06 06:18
A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering
LifeSci Capital Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-28
LifeSci Capital Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating
MT Newswires Live  ·  03-26
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
TIPRANKS  ·  03-25
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-19
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON)
CG Oncology Director James Mulay Disposes of USD 125,412 in Common Shares
Reuters  ·  03-18
CG Oncology Director James Mulay Disposes of USD 125,412 in Common Shares
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
Simply Wall St.  ·  03-16
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
CG Oncology price target raised to $72 from $65 at BofA
TIPRANKS  ·  03-14
CG Oncology price target raised to $72 from $65 at BofA
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-02
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029
Simply Wall St.  ·  03-02
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029
CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
TIPRANKS  ·  02-28
CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
CG Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  02-28
CG Oncology Is Maintained at Buy by HC Wainwright & Co.
Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M
MT Newswires Live  ·  02-27
Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate
Benzinga  ·  02-27
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate
CGON FY 2025 G&A expenses rise 118.1% to USD 73.5 million
Reuters  ·  02-27
CGON FY 2025 G&A expenses rise 118.1% to USD 73.5 million
CG Oncology Inc - Has $903 Mln Cash ,Cash Equivalents and Marketable Securities Sufficient to Fund Operations Into H1 2029
THOMSON REUTERS  ·  02-27
CG Oncology Inc - Has $903 Mln Cash ,Cash Equivalents and Marketable Securities Sufficient to Fund Operations Into H1 2029
Press Release: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
Dow Jones  ·  02-27
Press Release: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN)
TIPRANKS  ·  02-20
Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN)

Introduction

Company Name.
CG Oncology Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--